Maravai LifeSciences Holdings, Inc. is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics. The company operates through two segments: TriLink and Cygnus. TriLink supplies complex nucleic acids, including mRNA, oligonucleotides, and nucleoside triphosphates, along with proprietary CleanCap® mRNA capping and ModTail™ poly(A) tail modification technologies, specialty enzymes, and GMP manufacturing services. Cygnus offers biologics safety testing solutions, such as host cell protein ELISA kits, impurity detection assays, and viral clearance prediction tools using MockV® technology. Customers include biopharmaceutical companies, biotech firms, research organizations, and diagnostics companies globally. The company serves markets involved in cell and gene therapies, recombinant proteins, and vaccine development.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage maravai.com
Sector Healthcare IR page investors.maravai.com
Tags
mrna therapeutics, oligonucleotide synthesis, biologics safety testing, host cell protein detection, viral clearance prediction, nucleoside triphosphates, specialty enzymes, gene therapy, vaccine development, diagnostics, TriLink, Cygnus, CleanCap®, ModTail™, MockV®, MockV® MVM kit, MockV® RVLP Kit, CleanScript™, AAE™, TriLink BioTechnologies, Cygnus Technologies
Press page investors.maravai.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 1.142B
Market cap (USD) $ 1.142B
P/E -17.81
PEG —
P/BV 5.83
P/S 5.36
P/OCF -224.07
P/FCF -91.06
Dividend yield —
Turnover / mcap —
Returns  
ROE -48.6%
ROI -25.9%
ROIC -32.0%
Profit margin -70.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 75.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score -72.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 185.743M 259.185M 288.945M 883.001M 799.24M 284.098M
Net profit -130.773M -144.846M -119.029M 220.205M 182.037M 88.972M
Free cash flow -70.722M -22.193M 60.671M 518.887M 353.72M 126.779M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.25 5.45 6.55 14.31 41.9 28.05
Price performance 12m -0.4 -0.17 -0.54 -0.66 0.49 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 51M 118M 139M 54.6M 38.5M 25.5M
↳ YoY growth +130.3% +18.0% -60.6% -29.5% -33.8%
↳ 5y CAGR -13.0%
Borrowings, current (USD) — — 6M 6M 5.44M 5.44M 5.44M 5.44M
Borrowings, non-current (USD) — — 529M 525M 522M 519M 290M 286M
Lease liabilities (USD) — — 0.00 44.6M 57.8M 86.8M 80.8M 72.9M
Cash and deposits (USD) 21.9M 24.7M 236M 551M 632M 575M 322M 217M
Intangible assets (USD) — — 178M 118M 217M 221M 195M 152M
Right-of-use assets (USD) — — — 49.1M 63.9M 59.7M 52.6M 39.3M
Net debt (borrowings + leases - cash) (USD) — — 298M 23.9M -46.9M 36M 54.3M 148M
Cash flow detail
Operating cash flow (USD) — 24.1M 152M 369M 536M 126M 7.47M -57.6M
Purchases of property, plant and equipment (USD) — -17.1M -25.4M -14.9M -17.1M -65.6M -29.7M -13.1M
Purchases of intangible assets (USD) — — — — 0.00 0.00 -1.5M —
Change in receivables (cash effect) (USD) — -1.89M -33.1M -70.4M -22.3M 84.4M 14.4M 12.8M
Change in inventories (cash effect) (USD) — 106,000 -19.1M -21.6M 9.46M 649,000 377,000 8M
Change in payables (cash effect) (USD) — 2.47M 1.18M 676,000 -1.58M 5.28M 723,000 -7.35M
Share buybacks (cash effect) (USD) — 0.00 -33.7M 0.00 0.00 — — —
Interest paid (cash effect) (USD) — -28.7M -28.9M -27.2M -20.2M -44.3M -51M -25M
Income taxes paid (cash effect) (USD) — -802,000 -5.01M -22.5M -23M 2.99M -670,000 555,000
Share-based compensation (USD) — 1.68M 24.6M 10.5M 18.7M 34.6M 49.4M 30.2M
Operating cash flow before change in receivables (USD) — 26M 185M 439M 558M 41.8M -6.89M -70.4M
Free cash flow (OCF - PPE - intangibles) (USD) — 6.97M 127M 354M 519M 60.7M -23.7M -70.7M
Income detail
Research and development expense (USD) — 3.63M 9.3M 15.2M 18.4M 17.3M 19.2M 17.4M
↳ 5y CAGR +39.6% +13.3%
Total comprehensive income (USD) — -5.17M 78.8M 469M 491M -138M -145M -230M
Comprehensive income to owners (USD) — -4.44M 88.9M 182M 220M -119M -145M -130M
Reported Mar 1, 2022 Mar 1, 2022 Mar 1, 2022 Mar 1, 2022 Mar 18, 2025 Mar 18, 2025 Mar 18, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 04, 2026 4:01 PM EST Download as PDF

Related Documents

Earnings webcast

Audio

Presentation

PDF

GAAP/Non-GAAP reconciliation

PDF

10-Q Filing

HTML PDF

XBRL

ZIP

Third quarter 2026 total revenue up 10% from prior year

mRNA revenue up 28% year-over-year

SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates.

Key Financial Results:

  • Quarterly revenue of $45.9 million, Net loss of $(24.0) million, and Adjusted EBITDA of $5.8 million;
  • Full year 2026 revenue guidance range increased to $212.0 million to $216.0 million; Adjusted EBITDA guidance raised to $40.0 million to $42.0 million.

“Our third-quarter results build on the momentum we established in the first half of the year,” said Bernd Brust, CEO of Maravai LifeSciences. “TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%.”

Brust continued, “Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today’s Discovery success will create tomorrow’s GMP opportunity. Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance. We remain focused on driving sustained, profitable growth and creating long-term value for our shareholders.”

Revenue for the Third Quarter 2026

Three Months Ended September 30,
(Dollars in 000’s) 2026 2025 Year-over-Year %Change
TriLink $ 28,350 $ 25,353 11.8%
Cygnus 17,501 16,277 7.5%
Total Revenue $ 45,851 $ 41,630 10.1%

Revenue for the Nine Months Ended September 30, 2026

Nine Months Ended September 30,
(Dollars in 000’s) 2026 2025 Year-over-Year %Change
TriLink $ 110,495 $ 85,188 29.7%
Cygnus 52,635 50,689 3.8%
Total Revenue $ 163,130 $ 135,877 20.1%

Third Quarter 2026 Financial Results by Reporting Segment

Revenue for the third quarter was $45.9 million, an increase of 10.1% compared to the prior year period, driven by the following:

  • TriLink revenue increased 11.8% year-over-year, primarily driven by increased demand for Discovery mRNA and GMP consumables, as well as strength from our CDMO business.
  • Cygnus revenue increased 7.5% year-over-year, driven by increased demand for Host Cell Protein (HCP) and ELISA kits.

Net loss and Adjusted EBITDA (non-GAAP) were $(24.0) million and $5.8 million, respectively, for the third quarter of 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(45.1) million and $(10.8) million, respectively, for the third quarter of 2025.

Nine Months Ended September 30, 2026 Financial Results by Reporting Segment

Revenue for the nine months ended September 30, 2026 increased 20.1% compared to the prior year period, driven by the following:

  • TriLink revenue increased 29.7% year-over-year, primarily driven by $14.3 million of high-volume CleanCap orders for commercial phase COVID vaccine programs in Q1 2026. Excluding COVID CleanCap revenue, TriLink base revenue grew 12.9% year-over-year with increased demand for Discovery mRNA and GMP consumables.
  • Cygnus revenue increased 3.8% year-over-year, driven by demand for HCP and ELISA kits.

Net loss and Adjusted EBITDA (non-GAAP) were $(52.0) million and $34.8 million, respectively, for the nine months ended September 30, 2026, compared to net loss and Adjusted EBITDA (non-GAAP) of $(167.7) million and $(31.7) million, respectively, for the same period in the prior year.

Updated Financial Guidance for Full Year 2026

Maravai’s financial guidance for the full year 2026 is based on expectations for its existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is also subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below.

Revenue for the full year 2026 is now expected to be in the range of $212.0 million to $216.0 million, up from the prior range of $205.0 million to $215.0 million.

Adjusted EBITDA (non-GAAP) is now expected to be in the range of $40.0 million to $42.0 million, up from the prior range of $33.0 million to $35.0 million.

As it relates to forward-looking Adjusted EBITDA, Maravai cannot provide guidance for the most directly comparable GAAP measure or a reconciliation of this non-GAAP financial measure because it is unable to provide a meaningful or accurate calculation or estimation of certain significant reconciling items without unreasonable effort.

Conference Call and Webcast

Maravai’s management will host a conference call today at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results for the third quarter of 2026 and other business updates. To participate in the conference call by telephone, approximately 10 minutes before the call, dial 1-800-343-4849 or 1-203-518-9894 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com/ .

MARAVAI LIFESCIENCES HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(Unaudited)
Three Months EndedS****eptember 30, Nine Months EndedS****eptember 30,
2026 2025 2026 2025
Revenue $ 45,851 $ 41,630 $ 163,130 $ 135,877
Cost of revenue 29,659 35,975 92,587 114,729
Gross profit 16,192 5,655 70,543 21,148
Operating expenses:
Selling, general and administrative 30,502 35,456 91,664 113,735
Research and development 3,390 3,844 10,981 13,614
Goodwill impairment — — — 42,884
Restructuring 2,919 7,386 5,764 7,386
Total operating expenses 36,811 46,686 108,409 177,619
Loss from operations (20,619 ) (41,031 ) (37,866 ) (156,471 )
Other income (expense):
Interest expense (4,027 ) (6,844 ) (14,585 ) (20,437 )
Interest income 598 2,797 3,630 9,052
Loss on extinguishment of debt — — (3,413 ) —
Other expense (27 ) (71 ) (171 ) (4,109 )
Loss before income taxes (24,075 ) (45,149 ) (52,405 ) (171,965 )
Income tax benefit (75 ) (92 ) (397 ) (4,218 )
Net loss (24,000 ) (45,057 ) (52,008 ) (167,747 )
Net loss attributable to non-controlling interests (10,161 ) (19,501 ) (22,020 ) (72,655 )
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (13,839 ) $ (25,556 ) $ (29,988 ) $ (95,092 )
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $ (0.09 ) $ (0.18 ) $ (0.20 ) $ (0.66 )
Weighted average number of Class A common shares outstanding, basic and diluted 149,067 144,683 147,839 144,119
MARAVAI LIFESCIENCES HOLDINGS, INC.
RECONCILIATION OF NON-GAAP FINANCIAL INFORMATION(in thousands, except per share amounts)(Unaudited)
Net Loss to Adjusted EBITDA (non-GAAP)
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2026 2025 2026 2025
Net loss $ (24,000 ) $ (45,057 ) $ (52,008 ) $ (167,747 )
Add:
Amortization 6,466 7,209 19,407 21,439
Depreciation 5,737 5,975 15,950 17,625
Interest expense 4,027 6,844 14,585 20,437
Interest income (598 ) (2,797 ) (3,630 ) (9,052 )
Income tax benefit (75 ) (92 ) (397 ) (4,218 )
EBITDA (8,443 ) (27,918 ) (6,093 ) (121,516 )
Acquisition integration costs (1) 312 847 761 2,445
Stock-based compensation (2) 10,115 9,056 27,063 26,248
Merger and acquisition related expenses (3) — — — 1,270
Loss on extinguishment of debt — — 3,413 —
Acquisition related tax adjustment (4) — — — 4,082
Executive leadership transition costs (5) — 17 — 2,024
Goodwill impairment (6) — — — 42,884
Property and equipment impairment (7) — 7 — 1,059
Restructuring costs (8) 2,903 6,932 5,980 6,932
Other (9) 933 292 3,697 2,846
Adjusted EBITDA (non-GAAP) $ 5,820 $ (10,767 ) $ 34,821 $ (31,726 )
Net Loss attributable to Maravai LifeSciences Holdings, Inc. to Adjusted Net Loss (non-GAAP) and Adjusted Fully Diluted Loss Per Share (non-GAAP)
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2026 2025 2026 2025
Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (13,839 ) $ (25,556 ) $ (29,988 ) $ (95,092 )
Net loss impact from pro forma conversion of Class B shares to Class A common shares (10,161 ) (19,501 ) (22,020 ) (72,655 )
Adjustment to the provision for income tax (10) 2,486 4,644 5,388 17,304
Tax-effected net loss (21,514 ) (40,413 ) (46,620 ) (150,443 )
Acquisition integration costs (1) 312 847 761 2,445
Stock-based compensation (2) 10,115 9,056 27,063 26,248
Merger and acquisition related expenses (3) — — — 1,270
Loss on extinguishment of debt — — 3,413 —
Acquisition related tax adjustment (4) — — — 4,082
Executive leadership transition costs (5) — 17 — 2,024
Goodwill impairment (6) — — — 42,884
Property and equipment impairment (7) — 7 — 1,059
Restructuring costs (8) 2,903 6,932 5,980 6,932
Other (9) 933 292 3,697 2,846
Tax impact of adjustments (11) (160 ) 1,932 (2,973 ) (1,950 )
Adjusted net loss (non-GAAP) $ (7,411 ) $ (21,330 ) $ (8,679 ) $ (62,603 )
Diluted weighted average shares of Class A common stock outstanding (non-GAAP) 275,974 257,019 269,571 255,943
Adjusted loss (non-GAAP) $ (7,411 ) $ (21,330 ) $ (8,679 ) $ (62,603 )
Adjusted fully diluted loss per share (non-GAAP) $ (0.03 ) $ (0.08 ) $ (0.03 ) $ (0.24 )
____________________
Explanatory Notes to Reconciliations
(1) Refers to incremental costs incurred to execute and integrate completed acquisitions, including retention payments related to integration that were negotiated specifically at the time of the Company’s acquisition of Alphazyme, which was completed in January 2023. These retention payments were from the Company’s agreement executed in connection with its acquisition of Alphazyme and provided incremental financial incentives, over and above recurring compensation, to ensure the employees of Alphazyme remained present and participated in integration of the acquired business during the integration and knowledge transfer period. The Company agreed to pay certain employees of Alphazyme retention payments totaling $9.3 million as of various dates but primarily through December 31, 2025, as long as these individuals continued to be employed by the Company. The Company recognized compensation expense related to these payments in the post-acquisition period ratably over the service period, with certain costs capitalized into inventory. Retention payment expenses were $0.7 million and $2.2 million for the three and nine months ended September 30, 2025, respectively. Retention expenses for Alphazyme concluded in the fourth quarter of 2025, and following the payments in the fourth quarter of 2025, there were no further retention expenses payable for Alphazyme. There are no further cash-based retention payments planned as of September 30, 2026. The remaining expenses incurred reflect the impact to cost of revenue for the retention bonuses previously capitalized into inventory as the inventory is sold.
(2) Refers to non-cash expense associated with stock-based compensation.
(3) Refers to diligence, legal, accounting, tax and consulting fees incurred in connection with acquisitions that were pursued but not consummated.
(4) Refers to non-cash expense associated with adjustments to the indemnification asset recorded in connection with the acquisition of MyChem.
(5) Refers to costs associated with the Executive Leadership Transition that occurred in June 2025, including severance and legal costs. For the nine months ended September 30, 2025, stock-based compensation benefit of $(3.3) million primarily related to forfeited stock awards in connection with the Executive Leadership Transition is included on the stock-based compensation line item. For the three months ended September 30, 2025, there was no such stock-based compensation benefit amount.
(6) Refers to goodwill impairment recorded for our TriLink segment.
(7) Refers to non-cash charges to write-down surplus laboratory equipment to estimated fair value, less costs to sell.
(8) Refers to restructuring costs associated with the 2025 Corporate Realignment Plan. For the nine months ended September 30, 2026, stock-based compensation benefit of ($0.2 million) related to forfeited stock awards is included in the stock-based compensation line item. For the three months ended September 30, 2026 there was no such stock-based compensation benefit amount. For the three and nine months ended September 30, 2025, stock-based compensation expense of $0.5 million related to forfeited stock awards in connection with the 2025 Corporate Realignment Plan is included in the stock-based compensation line item. For the three and nine months ended September 30, 2026, there was a nominal amount of depreciation expense primarily related to the 2025 Corporate Realignment Plan is included in the depreciation line item. For the three and nine months ended September 30, 2025, there was no restructuring related depreciation expense.
(9) For the three and nine months ended September 30, 2026 and for the three and nine months ended September 30, 2025, refers to severance expense, inventory step-up charges in connection with the acquisition of Alphazyme, non-recurring legal costs, change in the estimated fair value of contingent consideration related to completed acquisitions, and other non-recurring costs that are deemed to be outside of the ordinary course of business.
(10) Represents additional corporate income taxes at an assumed effective tax rate of approximately 24% applied to additional net loss attributable to Maravai LifeSciences Holdings, Inc. from the assumed proforma exchange of all outstanding shares of Class B common stock for shares of Class A common stock.
(11) Represents income tax impact of non-GAAP adjustments at an assumed effective tax rate of approximately 24% and the assumed proforma exchange of all outstanding shares of Class B common stock for shares of Class A common stock.

Non-GAAP Financial Information

This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: Adjusted EBITDA and Adjusted fully diluted Earnings Per Share (EPS).

Maravai defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider representative of our ongoing operating performance from period to period. Maravai defines Adjusted Net Income (Loss) as tax-effected earnings before the adjustments described above, and the tax effects of those adjustments. Maravai defines Adjusted fully diluted EPS as Adjusted Net Income (Loss) divided by the diluted weighted average number of shares of Class A common stock outstanding for the applicable period, which assumes the proforma exchange of all outstanding units of Maravai Topco Holdings, LLC (paired with shares of Class B common stock) for shares of Class A common stock.

These non-GAAP measures are supplemental measures of operating performance that are not prepared in accordance with GAAP and do not represent, and should not be considered as, an alternative to net loss, as determined in accordance with GAAP.

Management uses these non-GAAP measures to understand and evaluate Maravai’s core operating performance and trends, and to develop short-term and long-term operating plans. Management believes the measures facilitate comparison of Maravai’s operating performance on a consistent basis between periods and, when viewed in combination with its results prepared in accordance with GAAP, help provide a broader picture of factors and trends affecting Maravai’s results of operations.

These non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for analysis of Maravai’s results as reported under GAAP. Because of these limitations, they should not be considered as a replacement for net loss, as determined by GAAP, or as a measure of Maravai’s profitability. Management compensates for these limitations by relying primarily on Maravai’s GAAP results and using non-GAAP measures only for supplemental purposes. The non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

October 29, 2026 4:01 PM EDT Download as PDF

SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November.

On November 12, 2026, at 10:40 a.m. EST, Raj Asarpota, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY.

On November 17, 2026, at 4:00 p.m. GMT, Raj Asarpota, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in London, England.

A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events, IR Calendar. An archived version of the webcast will also be available on the Maravai website after the event is completed.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

IR Calendar

Investors

Investors

Upcoming events

Nov 4, 2026 5:00 pm EDT

Q3 2026 Maravai LifeSciences Earnings Conference Call


Past events

Aug 6, 2026 5:00 pm EDT

Q2 2026 Maravai LifeSciences Earnings Conference Call


Jun 4, 2026 12:50 pm EDT

Jefferies Global Healthcare Conference in New York


May 26, 2026 2:30 pm PDT

2026 Annual Meeting of Shareholders


May 7, 2026 5:00 pm EDT

Q1 2026 Maravai LifeSciences Earnings Conference Call


View all past events

Maravai LifeSciences and its brands are the proven catalysts for helping deliver novel vaccines, therapeutics and diagnostics with biotech, biopharma and life sciences companies across the globe.

Extraordinary science.
Everyday miracles.

Connect with us

© 2026 Maravai LifeSciences. All rights reserved

Prompts

Maravai LifeSciences Holdings, Inc. (ticker MRVI), listed in United States.

ETFs Holding Maravai LifeSciences Holdings, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.15% 73,562 $ 562.014K Aug 31, 2026
VFMO 0.10% 239,807 $ 1.832M Aug 31, 2026
RESM 0.03% 181 $ 1,129.44 Jun 30, 2026
DFAS 0.01% 566,487 $ 4.351M Nov 12, 2026
DFSU 0.00% 8,779 $ 67.423K Nov 12, 2026
DCOR 0.00% 91,031 $ 699.118K Nov 12, 2026
DFUS 0.00% 32,054 $ 246.175K Nov 12, 2026
DFAC 0.00% 25,990 $ 199.603K Nov 12, 2026
DFAU 0.00% 1,337 $ 10.268K Nov 12, 2026